Vascular endothelial growth factor and its soluble receptor in ovarian pathology

Gynecol Endocrinol. 2005 Jul;21(1):50-6. doi: 10.1080/09513590500099560.

Abstract

Objective: The soluble form of the vascular endothelial growth factor (VEGF) receptor, s-VEGFR-1, may negatively regulate the action of VEGF. Our purpose was to better understand the regulation of angiogenetic processes in ovarian cysts.

Methods: Seventy-three women, 36 with serous cystoadenoma, 30 with ovarian endometriosis and seven with cystoadenocarcinoma, were enrolled. We calculated both VEGF and s-VEGFR-1 levels in cystic fluid and a VEGF activity index by means of the ratio VEGF/s-VEGFR-1. Student's t test was used for the statistical analysis.

Results: We found higher VEGF concentration in both endometriotic and malignant lesions than in serous cystoadenoma (p=0.03 and 0.001, respectively). Also s-VEGFR-1 concentration was higher in endometrioma than in serous cysts (p=0.005); however, there was no statistically significant difference between cystoadenoma and the malignant lesions (p=0.15). VEGF activity index in cystoadenoma, endometriotic and malignant lesions was 0.61, 0.27 and 0.50, respectively.

Conclusions: VEGF certainly has an important role in both ovarian endometriosis and for cancer progression; however, the activity index may be better to investigate the real role of VEGF in the pathology we have considered.

Publication types

  • Comparative Study

MeSH terms

  • Cyst Fluid / chemistry
  • Cystadenocarcinoma / chemistry
  • Cystadenoma, Serous / chemistry
  • Endometriosis / metabolism
  • Female
  • Humans
  • Ovarian Diseases / metabolism*
  • Ovarian Neoplasms / chemistry*
  • Vascular Endothelial Growth Factor A / analysis*
  • Vascular Endothelial Growth Factor Receptor-1 / analysis*

Substances

  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1